Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis
S M, Tabatabaei
S V, Behnava
N. Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis,
Online ahead of Print
Background: A head-to-head comparison of the 72-week and 48-week anti-HCV therapies in slow responders with genotype 1 infection has been performed in several randomized clinical trials (RCTs). Objectives: This review aimed at summarizing and pooling the results of these studies. Materials and Methods: RCTs that had evaluated the 72-week vs. 48-week anti-HCV therapy (peginterferon and ribavirin) in slow responders with HCV genotype 1 infection were systematically identified. A meta-analysis was performed using the random effects model. Heterogeneity in results was assessed on the basis of the Q statistics, and publication bias was evaluated by using Harbord's modified test. The end point was set as a sustained virological response (SVR). Results: Data of 1206 subjects were retrieved from 7 studies. A total of 631 patients had received extended therapy. Slow virological responders who received the 72-week therapy had a significantly higher probability of achieving SVR than their counterparts who received the 48-week therapy [RR = 1.44 (95% CI, 1.20-1.73)]. With regard to publication biases, the heterogeneity in funnel plots was not significant (P = 0.19, I 2 = 30%, P Harbord = 0.1). Conclusion: Our meta-analysis showed that the 72-week therapy with peginterferon and ribavirin is significantly superior to the standard 48-week therapy in slow responders with HCV genotype 1 infection. Keywords: Hepatitis C virus; Genotype; Treatments
Implication for health policy/practice/research/medical education:Treatment of hepatitis C is associated with eradication of 50% of the cases. Introduction of new methods for treatment of disease by increasing the duration of therapy can rise the chance of recovery. This article can be useful for all researchers in the field of gastroenterology, infectious disease and virology.
Please cite this paper as:Alavian SM, Tabatabaei SV, Behnava B, Mahboobi N. Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis. Hepat Mon. 2011;11(8):612-9. [DOI: 10.5812/kowsar.1735143X.721]
©2011 Kowsar M.P.Co. All rights reserved.
© 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.